Biomarker Study of Predicting the Efficacy of Anti-TNF-a Monoclonal Antibody Therapy in Crohn's Disease Patients Based on Multi-Omics Analysis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300073664

Enrollment

Unknown

Registered

2023-07-18

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Interventions

Response:No intervention

control:No intervention

Non-response:No intervention

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Crohn's Disease: 1. Aged between 18 to 65 years; 2. Diagnosed with Crohn's Disease based on history, physical examination, endoscopy and histopathological changes, treated with anti-TNFa therapy; 3. The patient voluntarily participates and signs the informed consent form. Non-IBD control: 1. Aged between 18 to 65 years; 2. For the population screened by endoscopy, there are no visible lesions under the colonoscope, or only benign polyps (single, no more than 2 cm in diameter, smooth surface and good mobility) are seen; 3. The patient voluntarily participates and signs the informed consent form.

Exclusion criteria

Exclusion criteria: combined with autoimmune diseases, malignancies or severe infection. Vulnerable groups, including individuals with mental illness, critically ill patients, pregnant women, minors, cognitive impairment, illiteracy, etc.

Design outcomes

Primary

Measure	Time frame
efficacy;transcriptome ;metabolome;	—

Countries

China

Contacts

Public ContactLingjie Huang

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

huanglingjie@zju.edu.cn+86 188 6810 0701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026